IWY357

Product vision
  • Uncomplicated malaria treatment and resistance management
MoA
  • Novel and unknown
Key features
  • No cross-resistance
  • No resistant mutants identified
  • Low predicted dose (<100 mg) and long predicted half-life in human
  • Fast killing in vitro and in vivo
Challenges
  • Partner drug selection
Status
  • Good Laboratory Practice (GLP) toxicology studies ongoing
  • Salt screen underway to develop final form
Next milestone
  • Completion of Good Laboratory Practice (GLP) toxicology programme
MMV Project Director
  • Dr Andrew Slade